Halozyme Therapeutics, Inc. (HALO) Comparison with companies in other sectors?

Halozyme Therapeutics, Inc. has a share price of 123.22M. You can analyze Halozyme Therapeutics, Inc. (HALO) competitors across different market sectors through stock heatmaps.

What are HALO's NET and operating margins?

Halozyme Therapeutics, Inc. (HALO) operating margin is around 0.55, and net profit margin is approximately 0.45 as of the latest reports.

In what way does HALO's earnings per share (EPS) trend reflect its financial momentum?

Halozyme Therapeutics, Inc. (HALO) EPS is 3.76 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Halozyme Therapeutics, Inc. is 15.49, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Halozyme Therapeutics, Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Halozyme Therapeutics, Inc. like P/E which is 14.84, P/B which is 14.93, and PEG which is 1.48. Compare them with sector averages to evaluate if the stock is priced fairly.

Halozyme Therapeutics, Inc.

HALO•NASDAQ

Healthcare

Biotechnology

$58.24

$-0.53(-0.90%)

Fundamental Analysis of Halozyme Therapeutics, Inc. (HALO)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$3.76

P/E Ratio

15.49

ROE

1.22%

Net Margin

0.45%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$7.18B

Shares OutstandingTotal number of shares issued

$123.22M

Book Value/ShareNet worth per share

$3.91

Revenue/ShareAnnual revenue per share

$8.80

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$3.76

Net MarginNet income as percentage of revenue

44.76%

Operating MarginOperating income as percentage of revenue

55.10%

ROEReturn on shareholders' equity

122.24%

ROAReturn on total assets

22.10%

ROCEReturn on capital employed

29.20%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$4.02

Cash/ShareCash and equivalents per share

$6.07

FCF YieldFree cash flow as percentage of market cap

6.90%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for HALOFinancial Ratios Analysis details for HALO are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for HALOSector Benchmarking details for HALO are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Halozyme Therapeutics, Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Halozyme Therapeutics, Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Halozyme Therapeutics, Inc.'s unique business strengths and challenges.

Key Financial Metrics for Halozyme Therapeutics, Inc.

For Halozyme Therapeutics, Inc., essential financial indicators include EPS 3.76, PE 15.49, and ROE 1.22. These key ratios reveal insights into Halozyme Therapeutics, Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Halozyme Therapeutics, Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Halozyme Therapeutics, Inc.

Metrics like Net Margin 44.76% and ROA 22.10% shed light on how well Halozyme Therapeutics, Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Halozyme Therapeutics, Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Halozyme Therapeutics, Inc.

Using ratios such as P/B Ratio 14.93 and PEG Ratio 1.48, investors can assess whether Halozyme Therapeutics, Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Halozyme Therapeutics, Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Halozyme Therapeutics, Inc.

Financial health indicators, such as Debt/Equity Ratio 3.13 and Cash Flow $4.02, provide a snapshot of Halozyme Therapeutics, Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Halozyme Therapeutics, Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Halozyme Therapeutics, Inc.

Investing in Halozyme Therapeutics, Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Halozyme Therapeutics, Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;